Division of Strategic Planning and Evaluation FY2022 List of Projects - Research Program on Emerging and Re-emerging Infectious Diseases
| First Year | Final Year | Principal Investigator | Affiliation | Project Title | |
|---|---|---|---|---|---|
| FY2020 | FY2022 | YASUDA Jiro | Nagasaki University | Professor | Studies on prevention, diagnostics and treatments for viral hemorrhagic fevers by collaborations between industry and academia |
| FY2020 | FY2022 | KAWAOKA Yoshihiro | The University of Tokyo | Professor | Development of next generation Ebola virus vaccines |
| FY2020 | FY2022 | MORIOKA Shinichiro | National Center for Global Health and Medicine | Doctor | Research on the establishment of a treatment and prevention system for Ebola hemorrhagic fever in Japan |
| FY2020 | FY2022 | KAGEYAMA Tsutomu |
National Institute of Infectious Diseases | Head | Study of improvement and practical application of rapid diagnosis of emerging respiratory viral infections |
| FY2020 | FY2022 | WATANABE Shinji |
National Institute of Infectious Diseases | Laboratory Chief | Establishment of a prediction method for seasonal influenza viruses based on their structure, antigenicity, and genetic information and its use for vaccine candidate selection |
| FY2020 | FY2022 | KAWASHIMA Hisashi |
Tokyo Medical University | Professor | Clinical and basic studies on pathophysiology of serious conditions of RS virus infection |
| FY2020 | FY2022 | MURAMATSU Masamichi |
National Institute of Infectious Diseases | Director | Study of comprehensive molecular epidemiology, prediction, and inapparent infection of viral diarrhea |
| FY2020 | FY2022 | SOMEYA Yuichi |
National Institute of Infectious Diseases | Chief | Virological and structural biological studies of diarrheal viruses for understanding mechanisms of viral replication and pathogenesis |
| FY2020 | FY2022 | KIYONO Hiroshi |
Chiba University | Distnguished Professor | Development of new generation mucosal prophylaxis and therapy against diarrheal viruses |
| FY2020 | FY2022 | Chang-Kweng Lim | National Institute of Health | Chief | Development research to contribute for comprehensive measures of Japan to control the current global epidemic of insect-borne virus diseases |
| FY2020 | FY2022 | HAMAGUCHI Isao |
National Institute Infectious Diseases | Director | Study of comprehensive effective strategy for HTLV-1 infection prevention |
| FY2020 | FY2022 | MATANO Tetsuro |
National Institute of Infectious Diseases | Director | Study for HTLV-1 vaccine development with elucidation of the HTLV-1 control mechanism |
| FY2020 | FY2022 | UCHIMARU Kaoru |
The University of Tokyo | Professor | Development of risk stratification and prevention for HTLV-1-associated diseases based on multi-omics database |
| FY2020 | FY2022 | KATO Seiya |
Research Institute of Tuberculosis, Japan Anti- Tuberculosis Association |
Director | Study of domestic tuberculosis control toward low incidence situation |
| FY2020 | FY2022 | TUYUGUCHI Kazunari |
National Hospital Organization Kinki-Chuo Chest Medical Center | Director | Study of innovative treatment strategy and ideal medical system for intractable and multidrug-resistant tuberculosis |
| FY2020 | FY2022 | ATO Manabu |
National institute of infectious diseases | Director | Study to develop prevention, diagnosis, and treatment of non-tuberculous mycobacterium diseases based on surveillance, genoume database,and clinical information |
| FY2020 | FY2022 | IKEBE Tadayoshi |
National Institute of Infectious Diseases | Senior researcher | Study on pathogenesis of streptococcal toxic shock syndrome and development of new therapeutics |
| FY2020 | FY2022 | KURODA Makoto |
National Institute of Infectious Diseases | Director | Research on development of AMR monitoring systems to hospital sewage, and social implementation of treatment system to reduce its environmental burden. |
| FY2020 | FY2022 | SUGAI Motoyuki |
National Institute of Infectious Diseases | Director | Development of Integrated Surveillance for Antimicrobial Resistance |
| FY2020 | FY2022 | YANAGIHARA Katsunori |
Nagasaki University | Professor | Study of diagnosis and therapy for antimicrobial resistance |
| FY2020 | FY2022 | Longzhu Cui | Jichi Medical University | Professor | Development of novel genetic testing, genotyping and therapeutic methods for implementing effective countermeasure against drug-resistant bacteria |
| FY2020 | FY2022 | MIYAZAKI Yoshitsugu |
National Institute of Infectious Diseases | Director | Investigation of breakthrough innovation for prevalence, novel diagnosis and treatment to overcome the invasive fungal infection by yeasts |
| FY2020 | FY2022 | HISAEDA Hajime |
National Institute of Infectious Diseases | Director | Research for surveillance and risk factors for domestic parasitic diseases |
| FY2020 | FY2022 | YAMAMOTO Masahiro |
Osaka University | Professor | Co-innovative Research and Development to Comprehend and Control Domestic Toxoplasmosis in Japan |
| FY2020 | FY2022 | NOZAKI Tomoyoshi |
The University of Tokyo | Professor | Drug and vaccine development against parasitic diseases endemic in Japan |
| FY2020 | FY2022 | OHNISHI Makoto |
National Institute of Infectious Diseases | Deputy Director General | Study of Establishment of Laboratory Response Network among The Research Institutions for Infectious Diseases in Asian Countries |
| FY2020 | FY2022 | NISHIURA Hiroshi |
Kyoto University | Professor | Study of expanding the use of mathematical models in infectious disease interventions |
| FY2020 | FY2022 | TAKAHASHI Yoshimasa |
National Institute of Infection Diseases | Director | Research and development of novel vaccines and therapeutics for influenza and rabies. |
| FY2020 | FY2022 | OSHIUMI Hiroyuki |
Kumamoto University | Professor | Study of development of small extracellular vesicle–based vaccine |
| FY2020 | FY2022 | YANAGIHARA Itaru |
Osaka Women's and Children's Hospital | Department Head | Study of a novel strategy for controlling preterm birth associated bacteria by using its bacterial restriction-modification system and the development of high sensitive bacterial nucleic acid amplification. |
| FY2020 | FY2022 | OKAMOTO Toru |
Osaka University | Professor | Development of anti-flavivirus compounds by targeting virus-specific life cycles. |
| FY2020 | FY2022 | KUNISAWA Jun |
National Institutes of Biomedical Innovation, Health and Nutrition | Director | Antibody library system for the design of vaccine, drug, and diagnosis and for the functional analysis of pathogens |
| FY2020 | FY2022 | SATO Kei | The University of Tokyo | Professor | Comprehensive survey of infectious microorganisms and the investigation of host responses against microorganism infections |
| FY2020 | FY2022 | NAKANO Satoshi |
National Institute of Infectious Diseases | Senior Researcher | Molecular characterization and genetic evolution of invasive and non-invasive pneumococcal strains recovered in Japan: the associations of genetic characteristics with disease severity |
| FY2020 | FY2022 | RIMBARA Emiko |
National Institute of Infectious Diseases | Senior Researcher | Non-Helicobacter pylori Helicobacter infections and their roles in human gastric disease |
| FY2020 | FY2022 | MURAKAMI Kosuke |
National Institute of Infectious Diseases | Senior Staff Researcher | Trial to develop a high-performance human norovirus cultivation system based on human intestinal organoids. |
| FY2021 | FY2023 | TAKAHASHI Hitoshi |
National Institute of Infectious Diseases | Senior Research Scientist | Study on cell-based influenza vaccine |
| FY2021 | FY2023 | MURAKAMI Shin |
University of Tokyo | Associate Professor | Study of preparedness for new MERS-like coronavirus outbreak |
| FY2021 | FY2023 | MIZUKAMI Takuo |
National Institute of Infectious Diseases | Section Chief | Research and Development of a Hyperimmune Globulin Product against Mother-to-Child Transmission of HTLV-1 |
| FY2021 | FY2023 | SUGAI Motoyuki |
National Institute of Infectious Diseases | Director | Studies on strengthening the AMR surveillance and the comprehensive promotion of countermeasures to AMR |
| FY2021 | FY2023 | OHNISHI Makoto |
National Institute of Infectious Diseases | Deputy Director General | Study of Antimicrobial resistance of Neisseria gonorrhoeae and Mycoplasma genitalium infections. |
| FY2021 | FY2023 | KOMATSUZAWA Hitoshi |
Hiroshima University | Professor | Study of the inhibition of colonization of drug-resistant bacteria in the oral cavity and upper respiratory tract |
| FY2021 | FY2023 | MITARAI Satoshi |
Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association | Professor/Head | A comprehensive basic study against difficult factors for tuberculosis control |
| FY2021 | FY2023 | HOSHINO Yoshihiko |
National Institute of Infectious Diseases | Division Chief | The development of novel treatment strategy regarding mechanism of latency and re-activation of mycobacterial infection using epidemiological observation |
| FY2021 | FY2023 | OKADA Masaji |
National Hospital Organization, Kinki-chuo Chest Medical Center | Visiting Senior Scientist | Study of a therapy (A Novel Therapeutic Vaccine) against tuberculosis and diagnosis for latent tuberculosis infection |
| FY2021 | FY2023 | MIYAZAKI Yoshitsugu |
National Institute of Infectious Diseases | Director-General, Director | Study of leprosy toward elimination and control |
| FY2021 | FY2023 | IYODA Sunao |
National Institute of Infectious Diseases | Chief | Research for the establishment of surveillance and virulence evaluation methods of diarrheagenic bacterial pathogen derived from severe cases |
| FY2021 | FY2023 | SUZUKI Motoi |
National Institute of Infectious Diseases | Director | Research on surveillance for vaccine-preventable diseases and the evaluation of vaccine effectiveness |
| FY2021 | FY2023 | KASAI Shinji |
National Institute of Infectious Diseases | Director of the Department | Studies on the arthropod vectors that transmit infectious diseases |
| FY2021 | FY2023 | ANDO Shuji |
National Institute of Infectious Diseases | Chief | Comprehensive study for tick-borne infectious diseases |
| FY2021 | FY2023 | MAEDA Ken |
National Institute of Infectious Diseases | Director | Comprehensive studies on countermeasure to companion animal-borne diseases |
| FY2021 | FY2023 | KUROSAKI Yohei |
Nagasaki University | Associate Professor | Study of practical biorisk management in the microbiological containment laboratories |
| FY2021 | FY2023 | FUKUHARA Takasuke |
Hokkaido University | Professor | Establishment of novel high-speed reverse genetics system for all RNA viruses |
| FY2021 | FY2023 | OGURA Yoshitoshi |
Kurume University School of Medicine | Professor | Development of new therapeutic and preventive strategy for Clostridioides difficile infection |
| FY2021 | FY2023 | UEMATSU Satoshi |
Osaka City University | Professor | Development of innovative phage therapy based on comprehensive metagenomic analysis |
| FY2021 | FY2023 | UCHIDA Satoshi |
Kyoto Prefectural University of Medicine | Associate Professor | Development of mRNA nano-vaccines possessing double-stranded RNA in mRNA side chains for pandemics |
| FY2021 | FY2023 | NAMKOONG Ho |
Keio University School of Medicine | Associate Professor | Elucidation of pathogenesis of NTM pulmonary disease based on integrated analysis of host and pathogen genomes |
| FY2021 | FY2023 | MISAWA Takashi |
National Institute of Health Sciences | Cheif | Study of middle-size drugs for multi-drug resistance bacteria |
| FY2021 | FY2023 | KATOH Hiroshi |
National Institute of Infectious Diseases | Chief | Elucidation of the neurotropic mechanism of mumps virus by identification of receptor glycans and its application to therapy |
| FY2022 | FY2024 | SHIMOJIMA Masayuki |
National institute of Infectious Diseases | Chief | Study on treatment against viral hemorrhagic fevers |
| FY2022 | FY2024 | EBIHARA Hideki |
National Institute of Infectious Diseases | Director | Integrated research for the establishment of a scheme to control emerging tick-borne viral diseases in Japan |
| FY2022 | FY2024 | KAWAOKA Yoshihiro |
University of Tokyo | Specially Appointed Professor | Evaluation of the therapeutic effects of novel compounds against highly pathogenic avian influenza viruses |
| FY2022 | FY2024 | ARITA Minetaro |
National Institute of Infectious Diseases | Chief | Integrated study on development of diagnostic, therapeutic, and preventive strategies for emerging and re-emerging enterovirus infections by multidiscipline research |
| FY2022 | FY2024 | MORI Yoshio |
National Institute of Infectious Diseases | Chief | Study of sustainable surveillance contributing to elimination of measles and rubella |
| FY2022 | FY2024 | MATSUOKA Masao |
Kumamoto University | Professor | Establishment of highly accurate prediction method for HTLV-1-associated diseases and development of dendritic cell therapy by ATL cell reprogramming |
| FY2022 | FY2024 | MORIKAWA Kazuya |
University of Tsukuba | Professor | Study of acquisition and stabilization of staphylococcal drug resistance |
| FY2022 | FY2024 | SHIN-YA Kazuo |
National Institute of Advanced Industrial Science and technology | Group Leader | A new strategy to create drugs to overcome multidrug-resistant bacteria using innovative natural compound derivatization technology |
| FY2022 | FY2023 | SHINTANI Yasunori |
National Cerebral and Cardiovascular Center | Director | Therapeutic development targeting drug-resistant Neisseria gonorrhoeae and Pseudomonas aeruginosa |
| FY2022 | FY2024 | IKEDA Haruo |
Next generation Natural Products Chemistry | Research Fellow | Derivatization and development of potent antimycobacterial agents by the next-generation technique |
| FY2022 | FY2024 | MAEDA Ken |
National Institute of Infectious Diseases | Director | Comprehensive studies on countermeasure to zoonoses and establishment of the network |
| FY2022 | FY2024 | ATO Manabu |
National institute of infectious diseases | Director | Study of antitoxins/antivenoms and their replacement by humanized monoclonal antibodies |
| FY2022 | FY2024 | KURODA Makoto |
National Institute of Infectious Diseases | Director | Study of comprehensive pathogen surveillance system based on the epidemiology and genome information |
| FY2022 | FY2024 | SUZUKI Tadaki |
Hokkaido University | Director | Pathological method development for congenital infections and unexplained illness of possible infectious etiology |
| FY2022 | FY2024 | MIZUNO Seiya |
University of Tsukuba | Associate Professor | Development of Fundamental Technology for the Generation of Genetically Humanized Mice as Pathogenic Animal Models for Emerging Viral Diseases |
| FY2022 | FY2024 | MARUYAMA Haruhiko |
University of Miyazaki | Professor | Establishment of medical care network for the adequate treatment of imported tropical diseases and rare parasitic infections in Japan |
| FY2022 | FY2024 | KAWAGUCHI Yasushi |
The University of Tokyo | Professor | Establishment of next-generation BAC system and high-speed analysis to accelerate the identification of notable mutant strains |
| FY2022 | FY2024 | KAWASE Takakazu |
Fujita Health University | Associate Professor | Development of universal T cell therapy for Cytomegalovirus (CMV) disease |
| FY2022 | FY2024 | KINOSHITA-Daitoku Ryo | Nagoya University Graduate School of Medicine | Assistant Professor | Development of innovative therapeutic agents for antimicrobial-resistant bacterial infections using the Ω systems |
| FY2022 | FY2024 | YAMAMOTO Mizuki |
The University of Tokyo | Senior assistant Professor | Identification of membrane fusion inhibitor for Dengue and Zika virus |
| FY2022 | FY2024 | MATSUNO Keita |
Hokkaido University | Lecturer | Development of comprehensive bunyavirus detection system for acute febrile illness |
| FY2022 | FY2024 | OHASHI Hirofumi |
National Institute of Infectious Diseases | Researcher | Research and development of the broad-spectrum antiviral compounds through targeting viral infection induced membrane compartment, double membrane vesicle |
| FY2022 | FY2024 | KIDOKORO Minoru |
National Institute of Infectious Diseases | Senior Researcher | Study on the development of a safer and more effective novel mumps vaccine derived from a current Japanese vaccine strain |
| FY2022 | FY2024 | KIMIZUKA Yoshifumi |
National Defense Medical College | Assistant Professor | Study of non-contact and non-invasive mucosal vaccine enhancing technology by near infrared laser |
| FY2022 | FY2024 | TSUJIMURA Yusuke |
National Institute of Infectious Diseases | Senior Research Scientist | Development of new tools for prevention of tuberculosis infection using recombinant BCG vaccine and nasal vaccine inducing mucosal immunity |
| FY2022 | FY2024 | ISHII Koji |
National Institute of Infectious Diseases | Director | Study of the establishment of quality control methods of existing vaccines |
| FY2022 | FY2024 | SUGA Shigeru |
National Hospital Organization Mie National Hospital | Vice Director | Basic, clinical, and epidemiological research that contributes to the verification of the usefulness of existing vaccines and the improvement of future vaccination measures |
| FY2022 | FY2024 | MATSUMOTO Koji |
Showa University School of Medicine | Professor | Study for monitoring the impact of a national HPV vaccination program in Japan (MINT study II) |
| FY2022 | FY2024 | EBIHARA Hideki |
National Institute of Infectious Diseases | Director | Establishment of animal models and evaluation schemes to develop medical countermeasures for viral hemorrhagic fevers |
| FY2022 | FY2024 | SENOH Mitsutoshi | National Institute of Infectious Diseases | Chief | Research for solidifying the infrastructure for the treatment, prevention, and diagnosis for rare bacterial infectious diseases |
| FY2022 | FY2024 | SHIME Nobuaki | Hiroshima University | Professor | Clinical evidence building for medical care support and development of new medical devices for severe COVID-19 patients using revised CRISIS platform |
| FY2022 | FY2024 | ABE Takaaki | Tohoku University | Professor | Study of mitochondria-based antiviral drugs for emerging and re-emerging infectious diseases |
09/01/22
Last updated 10/07/22